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Assessing somatization in urologic chronic
pelvic pain syndrome
C. S. North1,2*, B. A. Hong3, H. H. Lai4 and D. H. Alpers5
Abstract
Background: This study examined the prevalence of somatization disorder in Urological Chronic Pelvic Pain
Syndrome (UCPPS) and the utility of two self-report symptom screening tools for assessment of somatization in
patients with UCPPS.
Methods: The study sample included 65 patients with UCPPS who enrolled in the Multidisciplinary Approach to
the Study of Chronic Pelvic Pain (MAPP) Study at Washington University. Patients completed the PolySymptomatic
PolySyndromic Questionnaire (PSPS-Q) (n = 64) and the Patient Health Questionnaire-15 Somatic Symptom Severity
Scale (PHQ-15) (n = 50). Review of patient medical records found that only 47% (n = 30) contained sufficient
documentation to assess Perley-Guze criteria for somatization disorder.
Results: Few (only 6.5%) of the UCPPS sample met Perley-Guze criteria for definite somatization disorder. Perley-
Guze somatization disorder was predicted by definite PSPS-Q somatization with at least 75% sensitivity and
specificity. Perley-Guze somatization disorder was predicted by severe (> 15) PHQ-15 threshold that had > 90%
sensitivity and specificity but was met by only 16% of patients. The moderate (> 10) PHQ-15 threshold had higher
sensitivity (100%) but lower specificity (52%) and was met by 52% of the sample.
Conclusions: The PHQ-15 is brief, but it measures symptoms constituting only one dimension of somatization. The
PSPS-Q uniquely captures two conceptual dimensions inherent in the definition of somatization disorder, both
number of symptoms and symptom distribution across multiple organ systems, with relevance for UCPPS as a
syndrome that is not just a collection of urological symptoms but a broader syndrome with symptoms extending
beyond the urological system.
Keywords: Interstitial cystitis, Urological chronic pelvic pain syndrome, Chronic prostatitis, Somatization disorder,
Symptom screening, Psychiatric diagnosis, Polysymptomatic, Polysyndromic, Somatoform, Psychoform
Introduction
Urological chronic pelvic pain syndrome (UCPPS),
which includes interstitial cystitis/bladder pain syndrome
(IC/BPS) and chronic prostatitis/chronic pelvic pain syn-
drome (CP/CPPS), is a symptom-based syndrome with-
out objective testing or diagnostic biomarkers. UCPPS is
diagnosed only through assessment of symptoms and
symptom patterns reported by patients with this dis-
order. Bothersome symptoms characterizing UCPPS
include not only the core urological symptoms of pelvic
pain and urinary frequency/urgency but also an auxiliary
halo of non-urologic pain (e.g., abdominal pain) and
other symptoms extending beyond the urological system
(e.g., nausea, dizziness, or palpitations) [3, 6, 16, 17].
To avoid unnecessary medical tests, procedures, and sur-
geries, it is important to sort out symptoms of somatoform
disorders from medical illness, but this task has historically
proven difficult for both psychiatrists and non-psychiatric
physicians. Like many other functional disorders, UCPPS
has many symptoms in common with somatization dis-
order, and patients diagnosed with UCPPS may include
some patients who have somatoform disorders. In the
current version of American diagnostic criteria for psychi-
atric disorders, the Diagnostic and Statistical Manual of
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Mental Disorders, 5th edition (DSM-5), [2] the previous
diagnostic section on somatoform disorders was replaced
with a section covering somatic symptom and related disor-
ders; the former diagnosis of somatization disorder has
been replaced by somatic symptom disorder, which does
not require specified numbers of symptoms across organ
systems or symptoms that are “medically unexplained.”
Some patients with UCPPS report not just symptoms
confined to the definition of the syndrome but also mul-
tiple symptoms across multiple organ systems. One-fourth
of patients with UCPPS have been observed to have this
pattern of symptoms distributed widely across organ sys-
tems [16, 17]. This symptom presentation has been
termed “polysymptomatic, polysyndromic”, [17, 21] and it
is reminiscent of the classic presentation of somatization
disorder. Somatization disorder has historically been well
known to psychiatrists and other physicians as a chronic
disorder defined by the presentation of multiple symp-
toms distributed across many organ systems. To represent
somatization disorder, the symptoms had to be deter-
mined to have no medically explainable etiology. Like
UCPPS, somatization disorder requires documentation of
characteristic symptoms and symptom patterns reported
by patients, because there are no objective tests for bio-
markers to identify the disorder. For many years, these
two symptom-based syndromes may have coexisted with-
out recognition of the overlap between them.
The diagnosis of somatization disorder (under the name
Briquet’s syndrome) has historically been made using cri-
teria that were first established by Perley and Guze [23] and
formally validated in 1972 [7]. The Perley-Guze criteria are
recognized as the original, well-validated, and most com-
prehensive criteria for this diagnosis [7, 21, 23, 29]. The ori-
ginal Perley-Guze criteria continue to be accepted as valid
for diagnosis of somatization disorder, regarded by some
experts as superior to (and somewhat more stringent than)
the most recently established criteria [1] for the disorder
[21]. The Perley-Guze criteria remain meaningful today be-
cause psychiatrists and non-psychiatric physicians still need
to understand the clinical significance of the symptoms
their patients report. Although the Perley-Guze criteria
have no relevance for making a DSM-5 diagnosis of somatic
symptom disorder, their utility for sorting out symptoms
and symptom patterns is still important.
Various somatic symptom measures have been devel-
oped and used in different populations and settings for
assessment of somatic symptoms and somatization syn-
dromes. The PolySymptomatic PolySyndromic Ques-
tionnaire (PSPS-Q) developed by Lai et al. [17] has been
used in UCPPS research to identify not only the large
numbers of somatic symptoms reported by these pa-
tients but also their distribution across multiple organ
systems that are characteristic of somatoform disorders.
The PSPS-Q was conceptually derived from the Perley-
Guze criteria. The Patient Health Questionnaire-15
Somatic Symptom Severity Scale (PHQ-15, 13] has also
been used to assess somatization symptoms in patients
with UCPPS.
The purpose of this study was to examine the prevalence
of somatization disorder in UCPPS using the Perley-Guze
criteria and to compare two self-report symptom screening
tools—the PSPS-Q and the PHQ-15 to assist the evaluation
of UCPPS. Its findings should be of interest to many psy-
chiatrists, urologists, and primary care physicians who need
to evaluate the medical symptoms in their patients.
Methods
A sample of 65 patients with UCPPS was recruited from
consecutive patients presenting to the Washington Uni-
versity urology clinic in the early years of the Multidis-
ciplinary Approach to the Study of Chronic Pelvic Pain
(MAPP) project at one site. Study inclusion criteria were
1) age > 18 years, 2) report of an unpleasant sensation of
pain, pressure, or discomfort perceived by the patient to
involve the bladder and/or pelvic region and associated
with lower urinary tract symptoms, e.g., urgency, for
most of the time during the most recent 3 months, and
3) symptoms were not explained by another identifiable
urological cause. Exclusion criteria were active urinary
tract infection, cancer, urethral stricture, neurological
disease, fistula, radiation cystitis, cyclophosphamide cyst-
itis, urinary tuberculosis, or open bladder surgery. These
inclusion and exclusion criteria were adapted from the
MAPP Research Network working definition of UCPPS
[18]. Approval for this study was obtained from the In-
stitutional Review Board of Washington University, and
written informed consent was provided by all patients at
the time of their enrollment into the study.
Data for this study were collected between March 2010
and October 2012. As part of the MAPP study, partici-
pants provided information on demographics, symptom
duration; ratings of their pain; frequency and urgency on
0–10 numeric ratings scales; Interstitial Cystitis Symptom
and Problem Indexes [22]; the Genitourinary Pain Index
[4]; the Complex Medical Symptoms Inventory to assess
symptoms of irritable bowel syndrome (IBS) or fibromyal-
gia [28]; and a whole body map to characterize the loca-
tion and distribution of pain in the past week [15]. A full
list of data collected from the MAPP Epidemiology and
Phenotyping Study has previously been described [18].
The Washington University electronic outpatient
medical records of the patients in this sample were
reviewed by an expert psychiatric diagnostician (C.S.N.),
a urologist (H.H.L.), and an experienced medical/clinical
psychologist (B.A.H.) to formally assess Perley-Guze cri-
teria for somatization disorder. These 3 clinicians from
different areas of expertise provided multidisciplinary
consensus through interactive discussion of each
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patient’s medical history in the clinical records. A defin-
ite diagnosis requires > 25 symptoms in > 9 symptom
categories, but probable diagnosis (requiring > 20 symp-
toms in > 9 symptom categories) has been utilized his-
torically to include histories strongly suggestive of
somatization disorder but not quite meeting sufficient
numbers of symptoms [7, 23]. The probable diagnosis op-
tion was formalized for use in suboptimal circumstances
affording insufficient data for complete assessment—such
as the current study in which investigators were unable to
obtain data through collection of clinical information dir-
ectly from patients over long periods of time.
At the baseline clinic visit, demographic information
was recorded and the patients completed the PSPS-Q
and the PHQ-15. The PSPS-Q is a self-report symptom
questionnaire assessing 59 somatic symptoms across 10
symptom categories, derived from the 59-item yes/no
Perley-Guze symptom checklist and also requiring > 25
symptoms distributed among > 9 of 10 possible symp-
tom categories [20]. Only symptoms considered by the
patient to represent “a lot of trouble” are counted as
Perley-Guze symptoms. The PSPS-Q, unlike the original
Perley-Guze criteria historically used in clinical practice
and research, does not exclude medically unexplained
symptoms. The symptom count/symptom group scoring
algorithm used for determining the original Perley-Guze
criteria was applied for scoring the PSPS-Q data. Because
the 4 menstrual symptoms comprising 1 of the 10 Perley-
Guze symptom groups do not apply to men, the PSPS-Q
scoring threshold for men was reduced to > 21 symptoms
in > 8 categories for definite somatization and to > 16
symptoms in > 8 categories for probable somatization.
The PHQ-15 is a self-report symptom questionnaire de-
rived from the Patient Health Questionnaire that consists
of 15 items scored from 0 (“not bothered at all”) to 2
(“bothered a lot”), with scores of 5, 10, and 15 respectively
representing mild, moderate, and severe somatization. The
PHQ-15 has demonstrated validity and reliability and is
widely used for screening and monitoring somatization and
somatic symptom severity in clinical practice and research
[12–14, 25]. The moderate PHQ-15 threshold score of > 10
has been demonstrated to detect patients with medically un-
explained physical symptoms with 30% sensitivity and 93%
specificity, and with positive predictive and negative predict-
ive values (PPV and NPV) of .40 and .89 respectively [5].
The PSPS-Q was completed by 64 patients and the
PHQ-15 was completed by 50 of these patients. Probable
and definite self-report PSPS-Q somatization were not
associated with non-completion of the PHQ-15.
Statistical analysis
Data analysis for this study was conducted using SAS
version 9.4 (SAS Institute, Cary, NC). Descriptive find-
ings are represented as counts with proportions and
means with standard deviations (SD). Comparisons of
numerical variables with a dichotomous variable for sex
used Wilcoxon two-sample rank sum tests (PROC
NPAR1WAY WILCOXON in SAS) using t approxima-
tions with a continuity correction of 0.5. Dichotomous
variables generated by different forms of assessment
were compared through tests of sensitivity, specificity,
PPV, and NPV, as well as with chi-square tests.
Results
The 64 patients with PSPS-Q data and medical record
review was 48% male, 86% non-Hispanic white, 6% His-
panic, and 8% other race/ethnicity. The sample had a
mean (SD) age of 46.8 (16.1) years. The mean (SD) dur-
ation of UCPPS symptoms was 10.2 (12.0) years. IBS was
present in 30%, fibromyalgia in 8%, and chronic fatigue
syndrome in 13%. Mean (SD) ratings on a scale of 1–10
were 4.9 (2.4) for pain, 4.8 (2.8) for frequency, and 5.0
(2.6) for urgency. The mean (SD) genitourinary pain
index total score was 24.2 (9.6). The mean (SD) Intersti-
tial Cystitis Symptom and Problem Indexes were 9.5
(5.2) and 8.2 (4.6) respectively. The mean (SD) number
of body sites outside the pelvis that had pain was 3.8
(3.6) (of a maximum of 42 sites). Of the 34 female pa-
tients (52% of the sample), all had the clinical diagnosis
of interstitial cystitis/bladder pain syndrome (IC/BPS).
Of the 31 male patients (48% of the sample), 28 had the
clinical diagnosis of chronic prostatitis/chronic pelvic
pain syndrome (CP/CPPS), and 3 had the dual diagnoses
of IC/BPS and CP/CPPS.
The medical records of more than one-half of the pa-
tients (53%, 34/64) were found to contain insufficient
documentation (largely because of a lack of medical re-
cords by primary care providers and clinicians of other
disciplines) to allow the identification of patterns of mul-
tiple somatoform symptoms across multiple organ sys-
tems; thus, the medical records of only 30 patients could
be used to assess Perley-Guze criteria for somatization
disorder.
Somatization disorder was uncommon in this UCPPS
sample: only 2 patients (6.5%) met definite Perley-Guze
criteria based on medical record review. Two additional
patients (6.5%) met probable Perley-Guze criteria. All 4
of these patients were female.
The mean (SD) number of somatic symptoms on the
self-report PSPS-Q was 14.9 (11.2) and the mean (SD)
number of symptom groups was 6.4 (3.0). Men and
women did not differ on numbers of PSPS-Q symptoms
or symptom groups. One-third (33%, 21/64) of the sam-
ple met the threshold for at least probable PSPS-Q
somatization, including 17/64 (27%) with definite PSPS-
Q somatization. Insufficient medical record documenta-
tion was not associated with number of symptoms or
positive symptom groups reported on the PSPS-Q.
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Among the 30 patients with sufficient medical records,
11 (37%) met the probable PSPS-Q somatization thresh-
old, including 8 (27%) who met the definite threshold.
Medical record review found that 38% of the 8 patients
meeting the definite PSPS-Q threshold met Perley-Guze
criteria for somatization disorder (2 probable, 1 definite).
The fourth patient meeting (definite) Perley-Guze cri-
teria for somatization disorder by medical record review
was not forthcoming on the PSPS-Q, reporting only 2
symptoms in 1 symptom group.
Table 1 presents data for prediction of definite and prob-
able Perley-Guze somatization disorder criteria by medical
record review from definite and probable PSPS-Q
somatization. The definite PSPS-Q threshold was signifi-
cantly associated by chi-square test with probable Perley-
Guze somatization disorder, which it detected with sensitiv-
ity and specificity levels of at least 75% and positive predict-
ive value of 38%.
The mean (SD) PHQ-15 score was 8.7 (4.4), represent-
ing a mild-to-moderate level of somatization; 42% (21/
50) scored at or above the moderate threshold of 10 and
10% (5/50) scored at or above the severe threshold of 15.
PHQ-15 scores were higher for women than for men
(mean = 10.3, mean = 4.7 vs. mean = 6.7, SD = 2.9; z =
2.86, p = .004. Insufficient medical record documentation
was not associated with PHQ-15 scores.
Table 2 presents results for prediction of definite
Perley-Guze somatization disorder by medical record re-
view from PHQ-15 thresholds representing mild, moder-
ate, and severe somatization. (Because the 2 patients
with probable but not definite somatization disorder by
medical record review did not complete the PHQ-15,
prediction of probable somatization disorder by the
PHQ-15 was not possible.) The moderate PHQ-15
threshold > 10 identified 52% of the sample and
predicted definite Perley-Guze somatization disorder
with 100% sensitivity but only 52% specificity and a PPV
of only 15%, not meeting statistical significance by chi-
square test. A severe PHQ-15 score > 15, however, iden-
tified just 16% of the sample, and this threshold signifi-
cantly predicted definite Perley-Guze somatization
disorder by chi-square test with at least 90% for both
sensitivity and specificity, and with a PPV of 50%. Half
(2 of the 4) of the patients with a severe PHQ-15
score > 15 had definite Perley-Guze somatization dis-
order by medical record review.
Discussion
This study examined and compared data from a 59-item
self-report symptom questionnaire (PSPS-Q) and a 15-
item self-report screening questionnaire (PHQ-15) with
medical record review to assess Perley-Guze criteria for
somatization disorder in a sample of patients with
UCPPS. Medical record review by 3 experts confirmed
that 6.5% of the patients with UCPPS had definite and
another 6.5% had probable or definite somatization dis-
order. Thus, it was uncommon for UCPPS patients to
meet definite Perley-Guze criteria for somatization dis-
order (only 6.5%). This frequency is similar to the 1–6%
point prevalence of somatization disorder in primary
care patients reported by a recent systematic review that
identified, from a total of 992 publications, 32 studies
from 24 countries involving > 70,00 patients [9]. Self-
reported PSPS-Q somatization (both probable and defin-
ite thresholds) had higher sensitivity and specificity for
prediction of probable than for definite Perley-Guze
somatization disorder verified by medical record review.
Perley-Guze somatization disorder verified by medical
record review was predicted by both self-reported ques-
tionnaires. Probable Perley-Guze somatization disorder
was predicted by PSPS-Q definite somatization with at
least 75% sensitivity and specificity, and by moderate
(threshold > 10) PHQ-15 scores with higher sensitivity
(100%) but lower specificity (52%). These two compari-
sons were not completely comparable, however, because
the PSPS-Q comparison included patients with both def-
inite (n = 2) and probable (n = 2) Perley-Guze
somatization disorder but the PHQ-15 comparison could
not include the 2 probable Perley-Guze somatization
Table 1 Definite and probable PSPS prediction of definite and
probable Perley-Guze somatization disorder by medical record
review (n = 30)
Sensitivity Specificity PPV NPV p
Predicting definite Perley-Guze somatization disorder by medical record
review (7% of the sample)
Definite PSPS (27%
positive)
50% 75% 13% 95% .469
Probable PSPS (37%
positive)
50% 64% 9% 95% 1.000
Predicting probable Perley-Guze somatization disorder by medical rec-
ord review (13% of the sample)
Definite PSPS (27%
positive)
75% 81% 38% 95% .048
Probable PSPS (37%
positive)
75% 69% 27% 95% .126
PPV positive predictive value, NPV negative predictive value, PSPS
polysymptomatic, polysyndromic, PSPS-Q PSPS Questionnaire
Table 2 PHQ-15 prediction of definite Perley-Guze somatization
disorder by medical record review (n = 25)
Sensitivity Specificity PPV NPV p
PHQ-15 threshold
5 (92% positive) 100% 9% 9% 100% .664
10 (52% positive) 100% 52% 15% 100% .480
15 (16% positive) 100% 91% 50% 100% .020
PPV positive predictive value, NPV negative predictive value
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disorder cases who did not complete the PHQ-15. Neither
definite nor probable PSPS-Q somatization were signifi-
cantly associated with moderate or higher PHQ-15 scores.
The prediction of definite Perley-Guze somatization dis-
order by the PHQ-15 was statistically significant using a
higher PHQ-15 threshold (> 15, representing severe
somatization), with > 90% sensitivity as well as specificity.
Using the severe PHQ-15 threshold also substantially re-
duced the patient pool under consideration to 16% of all
patients versus 52% selected by the moderate PHQ-15
threshold. In summary, the PSPS-Q had greater sensitivity
but lower specificity than the moderate PHQ-15 threshold
that has been previously reported for identifying
somatization disorder, and a higher (severe) PHQ-15
somatization threshold performed better than the PHQ-
15 moderate somatization threshold for prediction of
Perley-Guze somatization disorder.
A limitation to attempting to assess somatization dis-
order criteria by any self-report questionnaire is that pa-
tients cannot be expected to determine whether their
own symptoms are medically explained or unexplained.
For this reason, self-report symptom questionnaires can-
not be used to diagnose somatization disorder [17, 21].
Two patient reporting behaviors further limit self-report
questionnaires: 1) patients with somatization disorder do
not report all their symptoms at once, focusing their
medical complaints on or even limiting them to the
organ system of the specialist, which necessitates collec-
tion of symptoms across different visits and to different
medical specialists [19, 20]; 2) these patients may pro-
vide medically plausible but incorrect explanations for
their symptoms and may even attribute their symptoms
to medical disorders they do not have [11, 19].
Limitations of this study include the small sample se-
lected in a treatment setting and investigated at a single
site from a specialty service at an academic institution
that may not be representative of other samples and set-
tings. Verification of diagnoses of somatization disorder
through medical record review was not possible for
more than half of the patients in this study because the
available patient records were limited to one or very few
visits to a limited set of providers, likely resulting in sub-
stantial underestimation. The small sample size coupled
with low numbers of patients meeting Perley-Guze cri-
teria for somatization disorder by medical record review
resulted in low power to detect subgroup differences; re-
gardless, analyses in this study suggested patterns of as-
sociation of symptom measures with the diagnosis of
somatization disorder which deserve further study with
larger samples in settings with more complete medical
records.
Not only has the traditional means of assessing diagnos-
tic criteria through medical record review been lost with
the evolution to current medical record systems, but the
diagnosis of somatization disorder itself has been lost from
established diagnostic criteria in DSM-5. This loss is still
controversial, and somatization disorder is recognized as
one of the few validated psychiatric disorders, consistently
included in previous versions of the manual (and remains
part of the International Classification of Diseases system).
This diagnosis was replaced in DSM-5 with somatic symp-
tom disorder, an unvalidated syndrome that is overly broad
and inappropriately inclusive of patients with nonpathologi-
cal distress attributable to medical illness [8, 10, 24, 26, 27].
Identifying patients with polysymptomatic, polysyndro-
mic symptom-reporting patterns characteristic of
somatization disorder in patient populations with
UCPPS is of clinical importance because their medical
outcomes are distinctly worse than those of other pa-
tients. These patients may require different clinical inter-
ventions, to avoid unnecessary medical tests, procedures,
and surgeries. The prevalence of somatization disorder
in UCPPS is unknown despite attempts to estimate it
using various symptom measures and methods.
Without the time-honored tools historically used to
identify somatization syndromes through detailed medical
records and longitudinal assessment of patients’ evolving
symptoms, other means of identifying patterns of
somatization are needed. The PSPS-Q or the PHQ-15
might be useful for identifying polysymptomatic, polysyn-
dromic presentations by completing a screening tool in
the pre-appointment waiting area to systematically ad-
dress symptoms outside the urinary system that are not
the focus of the brief clinical history gathered by urolo-
gists. This information might prompt urologists to collect
additional history to identify patterns of multiple symp-
toms distributed across multiple organ systems that is
characteristic of somatization disorder.
An advantage of the PHQ-15 over the PSPS-Q is that it
is less burdensome to complete, with only 15 items com-
pared to 59 in the PSPS-Q. However, the PSPS-Q
uniquely captures two conceptual dimensions inherent in
the definition of somatization disorder rather than one: it
not only counts the number of symptoms, but it also as-
sesses the extent of symptom distribution across multiple
organ systems that is integral to the conceptualization and
diagnosis of somatization disorder. Consideration not just
of number of symptoms but also their distribution across
organ systems has relevance for the appreciation of
UCPPS as a syndrome that is not just a collection of uro-
logical symptoms but a broader syndrome with symptoms
extending beyond the urological system.
Although the self-report PSPS-Q does not exclude
medically unexplained symptoms, the Perley-Guze
symptom algorithm has been found to retain its validity
even without this exclusion [29]. Brief symptom mea-
sures with as few as 15 items cannot be expected to as-
sess both the volume of symptoms and their distribution
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throughout the organ systems that is provided with the
59 symptom items of the PSPS-Q.
Conclusions
The PHQ-15 is brief, but it measures symptoms consti-
tuting only one dimension of somatization. The PSPS-Q
uniquely captures two conceptual dimensions inherent
in the definition of somatization disorder, both number
of symptoms and symptom distribution across multiple
organ systems, with relevance for UCPPS as a syndrome
that is not just a collection of urological symptoms but a
broader syndrome with symptoms extending beyond the
urological system. Few UCPPS patients (only 6.5%) met
definite Perley-Guze criteria for somatization disorder by
medical record review, but the PSPS-Q identified
somatization in 27% of the sample and the PHQ-15 se-
vere threshold identified somatization in 16%.
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